The summer of hydrogen sulfide: highlights from two international conferences by unknown
MEDICAL GAS 
RESEARCH
Calvert Medical Gas Research 2013, 3:5
http://www.medicalgasresearch.com/content/3/1/5COMMENTARY Open AccessThe summer of hydrogen sulfide: highlights from
two international conferences
John W CalvertAbstract
A great deal of interest has been paid recently to the hydrogen sulfide, the newest member of the gasotransmitter
family. With the growing interest in the biology of H2S, the need for meetings and conferences dedicated solely to
the field of H2S has also grown. In 2009, scientist from around the world met in Shanghai, China for the first time to
discuss the physiological relevance of H2S. In 2012, two conferences were organized to bring scientists, clinicians,
and industry representatives together to discuss the latest breakthroughs concerning the emergent field of H2S. The
following is a summary report of The First European Conference on the Biology of Hydrogen Sulfide and the
Second International Conference on Hydrogen Sulfide Biology and Medicine.
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Gasotransmitters are small, labile, endogenously-produced
gaseous molecules that play important roles in cellular
signaling [1]. Hydrogen sulfide (H2S) is the newest
member of the gasotransmitter family. Historically, it was
considered to be highly toxic and hazardous to the envir-
onment [2]. However, H2S has recently emerged as a
critical physiological gaseous signaling molecule that is
produced enzymatically in all mammalian species at low
micromolar levels via the action of cysteine metabolic
enzymes: cystathionine-γ-lyase (CSE), cystathionine-β
-synthase (CBS), and 3-mercaptopyruvate sulfutransferase
(3-MST) [3]. Because of this discovery, the biological and
physiological role of H2S has been re-evaluated. As such,
an extensive amount of work has been conducted over the
last several decades and has led to the discovery that H2S
possesses a number of physiological actions.
In 1989, while investigation the effects of acute H2S
poisoning in the brain, Warenycia et al. [4] first reported
that H2S was produced endogenously. Soon after this
discovery, other investigators started to take a closer
look at H2S and evidence soon emerged to demonstrate
its physiological importance. For instance, Skrajny et al.
[5] found increased levels of serotonin and reduced
levels of norepinephrine in the frontal cortex of a ratCorrespondence: jcalver@emory.edu
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reproduction in any medium, provided the orwhen chronically exposed to 20 ppm of H2S and in
1996, Abe et al. [6] suggested that H2S was an endogen-
ous neuromodulator, as they showed that physiological
concentrations of H2S enhanced N-methyl-D-aspartate
(NMDA) receptor-mediated responses and aided in the
induction of hippocampal long-term potentiation.
Shortly after, Hosoki et al. [7] reported that an H2S-pro-
ducing enzyme was present in the vasculature and
proposed that H2S may be an endogenous smooth
muscle relaxant. Since these initial offerings, studies
have begun to characterize its biological profile and
therapeutic potential. Over the last several years, a great
amount of work by investigators all over the world have
led to the suggestion that H2S is a powerful signaling
molecule with a diverse physiological profile. Moreover,
because of its physiological actions, H2S has been
reported to protect the heart, brain, liver, kidney, and
lungs against a variety of pathological stimuli, including
ischemia/reperfusion (I/R) injury [8-17].
With the growing interest in the biology of H2S, the
need for meetings and conferences dedicated solely to
the field of H2S has also grown. In 2009, scientists from
around the world met in Shanghai, China for the first
time to discuss the physiological relevance of H2S. In
2012, two conferences were organized to bring scientists,
clinicians, and industry representatives together to dis-
cuss the latest breakthroughs concerning the emergenthis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lights from those two meetings.
First European conference on the biology of hydrogen
sulfide
The First European Conference on the Biology of
Hydrogen Sulfide was held at Smolenice Castle on the
outskirts of Bratislava, Slovakia from June 15 to 18,
2012. The Institute of Molecular Physiology and Genet-
ics from the Slovak Academy of Sciences sponsored this
conference. Dr Karol Ondrias from the Slovak Academy
of Sciences served as the Conference Chairman and
Dr Matthew Whiteman from the University of Exeter
served as Honorary Chairman and Chairman of the
International Advisory Committee. Together with the
rest of the members of the International Advisory
Committee, Drs Ondrias and Whiteman organized an
outstanding scientific program consisting of 12 plenary
lectures, 34 short oral presentations, and 15 poster
presentations.
The meeting started with a Keynote Lecture delivered
by Dr Rui Wang from Lakehead University in Thunder
Bay, Ontario, Canada. In his lecture, Dr Wang discussed
several recent findings regarding where inside the
eukaryotic cell H2S is produced and how this intracellu-
lar compartmentalization is realized. He also discussed
the functional consequences of H2S production in res-
ponse to difference stimuli. Dr Wang’s lecture was
followed by a very nice welcome reception where the
attendees were inundated with local Slovakian cuisine.
Day 2 of the conference began with a session focused
on the effects of H2S on heart and vascular physiology.
Dr Y.Z. Zhu from Fudan University in Shanghai China
began the session by detailing recent work on the involve-
ment of H2S in the cardiovascular disorder processes and
the prospects of new therapeutic strategies based on the
regulation of endogenous H2S production [18]. This
session was highlighted by Dr David Lefer from Emory
University in Atlanta GA who presented recent work in-
vestigating the role of cystathionine gamma lyase derived
H2S in the development of pressure-induced heart failure.
He also presented novel and exciting data regarding the
effects of oral H2S therapy on preventing cardiac dysfunc-
tion following the induction of heart failure.
There is emerging evidence that members of the gaso-
transmitter family can interact with each other. For
instance, NO and H2S have been suggested to collaborate
in regulating vascular homeostasis and vasodilation. Add-
itional evidence suggests that NO can increase CGL activ-
ity acutely, and that chronic exposure to NO up-regulates
CGL expression. Moreover, at low concentrations H2S has
been shown to enhance the release of NO from vascular
endothelium and increase the vasorelaxant effect of the
NO donor sodium nitroprusside [19]. Furthermore, a 10fold increase in H2S levels have been reported with
administration of NO donors [20], suggesting a synergis-
tic relationship between NO and H2S. Dr Andreas
Papapetropoulos from the University of Patras in Greece
detailed very exciting and new results that further demon-
strate the interdependence of the gasotransmitters on each
other. Specifically, he provided the audience with compel-
ling evidence that angiogenesis and vasodilatation require
the simultaneous production of H2S and NO, suggesting
that both are mutually required for the control of vascular
function [21].
Day 2 concluded with two afternoon sessions. The first
session focused on the ability of H2S to regulate res-
piratory and gastrointestinal function. Dr John Wallace
from McMaster University in Hamilton, Ontario, Canada
discussed his group’s latest findings regarding the ability
of novel H2S releasing anti-inflammatory drugs to alleviate
the development of gastrointestinal (GI) ulcers [22]. The
last session of Day 2 focused on H2S donors and was
highlighted by Dr Mathew Whiteman’s presentation on
the use of H2S donors to treat inflammatory joint disease.
Dr Csabo Szabo from the University of Texas Medical
Branch in Galvaston, TX opened the morning session on
Day 3 by discussing the role of H2S deficiency in the
pathogenesis of diabetic vascular complications. In his
presentation he provided the audience with compelling
data suggesting that H2S deficiency is emerging as a sig-
nificant pathogenic mechanism in diabetic complication,
while H2S supplementation has the potential to be a
novel therapeutic approach [23]. The session on H2S
and diabetes was followed by a session regarding the
interaction of H2S with the mitochondria. This session
was highlighted by Dr Katalin Modis’ (University of
Texas Medical Branch in Galvaston, TX) presentation
detailed her exciting work demonstrating that H2S has a
physiological role as a positive modulator of mitochon-
drial electron transport that is dependent on a basal
activity of the Krebs cycle [24].
In the afternoon, Dr Hideo Kimura from the National
Institute of Neuroscience in Tokyo, Japan led off a very
interesting and stimulating session on the synthesis of
hydrogen sulfide. In his talk, Dr Kimura detailed his
group’s efforts to identify the endogenous reducing
substances (thioredoxin and dihydrolipoic acid) that fa-
cilitate the production of H2S from 3-mercaptopyruvate
sulfurtransferase [25]. This was followed by a very stimu-
lating presentation from the Ondrias group detailing their
work suggesting that H2S induces the release of NO from
nitroso groups. Day 3 ended with a very informative
session regarding the interaction of H2S with different ion
channels.
The Final Day of the conference ended with several
talks discussing the latest findings regarding the role of
H2S in the setting of cellular stress and cell proliferation.
Calvert Medical Gas Research 2013, 3:5 Page 3 of 5
http://www.medicalgasresearch.com/content/3/1/5Additionally, awards were handed out at the conclusion
of the conference to several young investigators.
The second international conference on H2S biology and
medicine
With the momentum gained at Smolenic Castle in Brati-
slava, scientists, clinicians, and industry representatives
from around the world descended on Atlanta, GA from
September 20 – 22, 2012 to attend the Second Inter-
national Conference on H2S Biology and Medicine. Dr
David Lefer from Emory University in Atlanta, GA
organized this conference. Together with the rest of the
member of the Organizing Committee, Dr Lefer planned
a well-balanced scientific program detailing the latest
findings concerning the chemistry and biology of H2S.
The final program consisted of 30 plenary lectures, 4 short
oral presentations, and over 75 poster presentations.
Dr Solomon Snyder from Johns Hopkins University in
Baltimore, MD delivered the keynote lecture to start the
conference. In his lecture, Dr Solomon eloquently dis-
cussed his group’s efforts to characterize sulfhydration,
which is the mechanism by which H2S modifies reactive
cysteine residues on targeted proteins. Although analo-
gous to protein nitrosylation, sulfhydration is substantially
more prevalent and usually increases the catalytic activity
of targeted proteins [26].
Dr Snyder’s lecture was followed by several presen-
tations on the biology and chemistry of H2S. Highlights
from this session included Dr Nicholas Tonk’s (Cold
Spring Harbor Laboratory) presentation on his recent
work detailing of the effects of H2S on the endoplasmic
reticulum stress response. Specifically, he presented data
demonstrating that H2S reversibly inhibits the activity of
protein tyrosine phosphatase 1B, which promotes the ac-
tivity of protein kinase-like endoplasmic reticulum (ER)
kinase (PERK) during the response to ER stress [27].
With the growing interest in the physiological and bio-
logical role of H2S, there is a need for better detection
methods for H2S levels and signaling. This was a constant
point of discussion throughout the meeting. As such, Dr
Ming Xian’s (Washington State University in Pullman,
WA) presentation on new chemical tools for H2S research
was of particular interest. In his talk, Dr Xian provided
evidence that newly developed fluorescent probes provide
good selectivity and sensitivity for H2S [28].
The afternoon session of Day 1 was dedicated to dis-
cussion on the role that H2S plays in the development
and treatment of cardiovascular disease. Dr Frank Sellke
from Brown University in Providence, RI led off this ses-
sion by discussing his labs previous work investigating
the impact of H2S on myocardium in the setting of cold
crystalloid cardioplegia and cardiopulmonary bypass
[29]. In his talk, Dr Sellke provided compelling evidence
that treatment with H2S offered myocardial protectionvia attenuation of caspase-independent apoptosis and
autophagy in a porcine model of cardiopulmonary by-
pass. Later in this session, Dr Suresh Tyagi from the
University of Louisville in Louisville, KY summarized his
groups’ findings regarding the effects of H2S on cardio-
vascular remodeling in response to heart failure [30].
Day 1 concluded with a reception and presentation of
posters.
Day 2 of the conference featured three sessions. The
first session of the morning was focused on H2S and the
vasculature. Dr Rui Wang from Lakehead University in
Thunder Bay, Ontario, Canada started the session with a
nice introduction to the effects of H2S on the vascular
endothelium. This was followed by Dr Guiseppe Cirino’s
(University of Naples, Naples, Italy) presentation on H2S
as an endogenous inhibitor of phosphodiesterases and
how this affects vascular tone.
The second session of Day 2 was focused on the H2S
and gastrointestinal diseases. Presentations in this ses-
sion from Drs. John Wallace (McMaster University in
Hamilton, Ontario, Canada), Mauro Perretti (Queen
Mary University), Nathalie Vergnolle (INSERM), and
Andre Buret (University of Calgary) detailed the latest
findings regarding the role of H2S in the resolution and
repair of the GI tract and detailed the latest deve-
lopments in use of novel H2S releasing drugs to treat GI
disorders.
The final session of Day 2 was concentrated on the
role of H2S in shock and sepsis. This session began with
a very informative presentation by Dr Konstantin
Shatalin (New York University) in which he discussed
the role H2S plays in mediating bacteria defense against
antibiotics [31]. Specifically, Dr Shatalin provided evi-
dence that inactivation of putative cystathionine β-
synthase, cystathionine γ-lyase, or 3-mercaptopyruvate
sulfurtransferase in Bacillus anthracis, Pseudomonas
aeruginosa, Staphylococcus aureus, and Escherichia coli
suppresses H2S production, rendering these pathogens
highly sensitive to a multitude of antibiotics. Dr Fumito
Ichinose from Harvard University in Boston, MA then
detailed recent findings from his lab in which they
demonstrated that inhaled H2S prevents inflammation
and improves survival in the setting of endotoxemia by
altering sulfide metabolism in mice [32].
The final day of the conference began with presen-
tations selected from submitted abstracts. This forum
gave deserving young investigators and trainees the
opportunity to present their latest findings in a more
formal setting. This session was followed by a second
session on H2S and the vasculature. Dr Christopher
Peers from the University of Leeds in Leeds, England
highlighted this session with his presentation on the
regulation of ion channels by H2S. Dr Chris Kevil from
LSU-Health Sciences Center in Shreveport, LA delivered
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work on the actions of H2S in the setting of high limb
ischemia.
Summary and comments
In summary, the First European Conference on the Biology
of H2S and the Second International Conference on H2S
Biology and Medicine were both a tremendous successes.
Each conference provided an excellent platform for the
presentation and discussion of the latest findings regarding
the biology and chemistry of H2S. In addition, both of
these conferences served as a reminder that that is still so
much about H2S that we do not know. In this regard, a
number of important issues/questions were raised at each
conference that will certainly drive research in the years to
come. These include (1) the need to develop more sensitive
ways to measure H2S, (2) the need to develop new drugs
or delivery mechanisms to deliver sustained levels of H2S,
and (3) the need to understand the molecular targets of
H2S and the manner in which H2S modifies these cellular
targets.
It was recently announced that there will be a Second
European Conference in Exeter England from September
8–11, 2013. Dr Matthew Whiteman will serve as the
Organizer. In addition, Dr Hideo Kimura will serve as
the organizer for the next International H2S meeting. He
announced at the conclusion of the Atlanta meeting that
the next International conference on H2S will be held in
Japan in 2014. For more information about this confer-
ence and other conferences related to H2S please log on
to the European Network on Gasotransmitters website
for the latest news and developments (http://www.
gasotransmitters.eu/).
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